Lilly Joins Psychedelic Drug Race With AtaiBeckley Buyout – Merger Arbitrage Mondays
AtaiBeckley Inc. (ATAI): $7.22 Market Cap: $2.66 B Deal Value: $2.8 B Eli Lilly and Company (LLY) entered into a merger agreement on July 16, 2026, to acquire AtaiBeckley in a…
Written byAsif SuriaSource: InsideArbitrage
AtaiBeckley Inc. (ATAI): $7.22 Market Cap: $2.66 B Deal Value: $2.8 B Eli Lilly and Company (LLY) entered into a merger agreement on July 16, 2026, to acquire AtaiBeckley in a deal valued at $2.8 billion, joining a growing race among pharmaceutical giants to develop psychedelic therapies for depression and other mental health conditions. The deal